Journal Article Review Research Support, Non-U.S. Gov't Ppublish 1 citation
PubMed: 39680873 DOI: 10.1021/acssensors.4c02280
A Review on Long COVID Screening: Challenges and Perspectives Focusing on Exhaled Breath Gas Sensing.
ACS Sens 10(3):1564-1578
Authors: Lorena Díaz de León-Martínez, Gabriela Flores-Rangel, Luz E Alcántara-Quintana, Boris Mizaikoff
Affiliations
- Institute of Analytical and Bioanalytical Chemistry, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany. Breathlabs Inc. Spring, Texas 77386, United States.
- Institute of Analytical and Bioanalytical Chemistry, Ulm University, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
- Unidad de Innovación en Diagnóstico Celular y Molecular, Coordinación para la Innovación y la Aplicación de la Ciencia y Tecnología, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona 550, Lomas 2a sección, 78120, San Luis Potosí, México.
- Hahn-Schikard, Sedanstrasse 14, 89077 Ulm, Germany.
Abstract
Long COVID (LC) is a great global health concern, affecting individuals recovering from SARS-CoV-2 infection. The persistent and varied symptoms across multiple organs complicate diagnosis and management, and an incomplete understanding of the condition hinders advancements in therapeutics. Current diagnostic methods face challenges related to standardization and completeness. To overcome this, new technologies such as sensor-based electronic noses are being explored for LC assessment, offering a noninvasive screening approach via volatile organic compounds (VOC) sensing in exhaled breath. Although specific LC-associated VOCs have not been fully characterized, insights from COVID-19 research suggest their potential as biomarkers. Additionally, AI-driven chemometrics are promising in identifying and predicting outcomes; despite challenges, AI-driven technologies hold the potential to enhance LC evaluation, providing rapid and accurate diagnostics for improved patient care and outcomes. This review underscores the importance of emerging and sensing technologies and comprehensive diagnostic strategies to address screening and treatment challenges in the face of LC.
MeSH
Electronic Nose, Covid-19, Diagnosis, Therapeutics, Artificial Intelligence, Post-Acute Covid-19 Syndrome